While I hope you are right that many PWME will benefit from Rituximab, I also hope it will not be the end-all treatment for ME/CFS. At present there is something like a 33% non-responder rate. Add to that the fact that a fair number of us will not be able to take Ritux because we have contraindicating conditions, it is likely that more than 50% of us will not benefit from Ritux for one reason or another.
A 33% non-responder rate, if it turns out to be true in a larger cohort, is basically a home run by pharma standards. Most drugs on the market have an approx. 30-40% responder rate.
Brincidofovir is interesting because it will replace Valcyte and will already be on the market by the time the rituximab trials are completed. I believe unless there is some kind of drug interaction we will be able to take both rituximab and brincidofovir together.
Unlike Valcyte, I believe brincidofovir is not immunosuppressive. Even if Kogelnik wants to combine Valcyte with Rituximab it will be complicated because Valcyte causes immunosuppression incl neutropenia, so will be touch and go with many patients having to closely monitor CBC w diff.
Last edited: